7th Apr 2016 09:30
Skyepharma PLC - Annual Report and Accounts 2015
LONDON, UK, 7 April, 2016 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, today announces that in accordance with the Listing Rules, copies of the following documents have been submitted to the National Storage Mechanism:
· Annual Report and Accounts 2015
· Notice of Annual General Meeting
· Form of Proxy
These documents will shortly be available for inspection at the National Storage Mechanism at www.morningstar.co.uk/uk/NSM
The Annual Report and Accounts and Notice of Annual General Meeting are also available on the Company website at www.skyepharma.com
The Annual General Meeting will be held at 10.30 a.m. on Wednesday 18 May 2016 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD.
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 (0)20 7881 0524 |
Jonathan Birt, Investor and Media Relations
| +44 (0)7860 361746 |
N+1 Singer | |
Shaun Dobson/Jen Boorer | +44 (0)20 7496 3000 |
FTI Consulting | |
Julia Phillips/Rob Winder/Natalie Garland-Collins | +44 (0)20 3727 1000 |
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com
Related Shares:
SKP.L